Interim Managing Director DACH
Medical technology / pharmaceutical industry
International group of companies
The company’s DACH organization showed declining sales and revenue figures, and EBIT was clearly negative. A clear sales strategy was not in place, and internal cooperation with the product development, quality assurance and production departments was clearly strained.